Rishi Fibc Solution Private Limited
Nanjangud, Mysuru, Karnataka
GST No. 29AADCR5130N1Z2
TrustSEAL Verified
Call 0794253182827% Response Rate
SEND EMAIL
Product Details:
| Strength | 5 mg |
| Packaging Size | 0.5 ml |
| Brand | Mounjaro |
| Packaging Type | Injection |
| Manufacturer | Eli Lilly and Company |
| Brand | Mounjaro |
| Manufacturer | Eli Lilly and Company |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Product Details:
| Strength | 100 IU/ml |
| Dose/Strength | 2mg |
| Form | Injection |
| Packaging Type | Box |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Product Details:
| Strength | 2.5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Injection |
| Brand | Mounjaro |
| Manufacturer | Eli Lilly and Company |
| Manufacturer | Eli Lilly and Company |
| Prescription | Yes |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Product Details:
| Strength | 7.5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Pre-filled pen |
| Brand | Mounjaro |
| Manufacturer | Eli Lilly and Company |
| Manufacturer | Eli Lilly and Company |
| Prescription | Yes |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Product Details:
| Strength | 7.5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Pre-filled pen |
| Brand | Mounjaro |
| Manufacturer | Eli Lilly and Company |
| Prescription | Yes |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.